Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.
By E. Small, Paul Schellhammer, Celestia S. Higano, C. Redfern, J. Nemunaitis, F. Valone, S. Verjee, L. Jones, R. Hershberg. Journal of Clinical Oncology, 2006
1,121 citations recorded by the source corpus.
Subfields: Immunology, Oncology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/697bcf9beb04ec653da70e32ed764543c689690e
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- J. Gulley
- D. Bilhartz
- William L Dahut
- Brent A. Blumenstein
- L. Glode
- P. Kantoff
- W. Godfrey
- K. Manson
Citations in the corpus
- Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. (2010, positive): “4 months for controls) and OS benefit (3-year OS of 33% v 11%), yet demonstrated only a trend toward delayed short-term disease progression.(16) A larger phase III study with more than 500 patients has recently confirmed these results.”